Genesis Biopharma, Inc (GNBP) is a publicly traded company in the Unknown sector. Across all available filings, 8 corporate insiders have executed 16 transactions totaling $2.2K, demonstrating a bullish sentiment with $2.2K in net insider flow. The most recent transaction on Jul 24, 2013 involved a transaction of 13,353,215 shares valued at $0.
No significant insider buying has been recorded for GNBP in the recent period.
No significant insider selling has been recorded for GNBP in the recent period.
Based on recent SEC filings, insider sentiment for GNBP is bullish with an Insider Alignment Score of 100/100 and a net flow of $2.2K. Insiders are accumulating shares, which historically signals confidence in the company's future performance.
Insider trading at Genesis Biopharma, Inc (GNBP) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 8 insiders are actively trading GNBP stock, having executed 16 transactions in the past 90 days. The most active insider is Capital Management, Lp Ayer (Executive), who has made 2 transactions totaling $27.4M.
Get notified when executives and directors at GNBP file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Jul 24, 2013 | Kessler Paul | Executive | Award | 13,353,215 | $N/A | $0 | |
| Jul 24, 2013 | A/ Mcpeak Merrill | Executive | Award | 13,353,215 | $N/A | $0 | |
| Jul 24, 2013 | J. Voyticky David | Executive | Award | 13,353,215 | $N/A | $0 | |
| May 22, 2013 | Management, Lp Ayer Capital | Executive | Other | 5,600,887 | $4.90 | $27.4M | Large |
| May 22, 2013 | Management, Lp Ayer Capital | Executive | Other | 0 | $0.05 | $0 | |
| May 22, 2013 | A/ Mcpeak Merrill | Executive | Other | 21,280,000 | $N/A | $0 | |
| May 22, 2013 | J. Voyticky David | Executive | Other | 5,627,867 | $N/A | $0 | |
| May 22, 2013 | J. Voyticky David | Executive | Other | 50,000 | $N/A | $0 | |
| May 22, 2013 | Fund Ltd Bristol Investment | Executive | Other | 0 | $N/A | $0 | |
| Dec 31, 2012 | Fund Ltd Bristol Investment | Executive | Purchase | 10,000 | $0.22 | $2.2K | |
| Mar 29, 2011 | Mckilligan Richard | Executive | Other | 1,500,000 | $N/A | $0 | |
| Mar 25, 2011 | T. Brooke Robert | Executive | Other | 1,500,000 | $N/A | $0 | |
| Mar 31, 2010 | Hamilton Atlantic | Executive | Other | 5,854,753 | $N/A | $0 | |
| Mar 31, 2010 | Hamilton Atlantic | Executive | Other | 5,854,753 | $N/A | $0 | |
| Mar 31, 2010 | Hamilton Atlantic | Executive | Other | 3,395,757 | $N/A | $0 |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Other(J) | 12 | $27.4M | 100.0% |
Purchase(P) | 1 | $2.2K | 0.0% |
Award(A) | 3 | $0 | 0.0% |
Insiders at Genesis Biopharma, Inc are accumulating shares at an accelerated pace. With 8 insiders making 16 transactions totaling $2.2K in purchases versus $0 in sales, the net buying activity of $2.2K signals strong executive confidence. Capital Management, Lp Ayer (Executive) leads the buying activity with $27.4M in transactions across all time.